[Management of T1G3 tumours of the bladder].
T1G3 tumours are the most aggressive superficial tumours of the bladder, with a high risk of recurrence and progression. Complete endoscopic resection of the tumour is the first diagnostic and therapeutic step in T1G3 management. A second resection should be done at 1 month to avoid residual tumour and misdiagnosis of a muscle infiltrative cancer. As a result of treatment by instillations of Calmette and Guérin bacillus following endoscopic resection, a 5-year survival rate of 80% has been reported, with 50 to 60% of bladder preservation. BCG is the only conservative treatment that has proven effectiveness on both tumour recurrence and progression. Long term protocols seem to give the best results. Endovesical chemotherapy is not commonly used as its impact on progression has not been demonstrated. Radical cystectomy can be chosen as first line treatment in patients with particularly aggressive tumours. Long term and close surveillance should be achieved in every patient.
Bensalah
K
K
Hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes, France.
Patard
J J
JJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D006801:Humans; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine